# HS-10241-301 (NCT06110663)

> A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06110663
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: HS-10241+ Almonertinib; Pemetrexed + Cisplatin /Carboplatin
- Enrollment: 314
- Primary outcome: Progression-free Survival (PFS) evaluated by Independent Review Committee (IRC)

## Indexed commentary on HS-10241-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=hs-10241-301-nct06110663